Viral Vector News and Research RSS Feed - Viral Vector News and Research

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.
Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official change of its name to the Cell and Gene Therapy Catapult. [More]
New gene cut-and-paste methods help correct disease-causing mutation in animal model

New gene cut-and-paste methods help correct disease-causing mutation in animal model

For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected. [More]
New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans. [More]
Synpromics, Cell Therapy Catapult to create stable producer cell lines for large-scale manufacture of viral vectors

Synpromics, Cell Therapy Catapult to create stable producer cell lines for large-scale manufacture of viral vectors

Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and increasing the scale and efficiency of viral vector manufacturing. [More]
Alpha-synuclein protein involved in Parkinson's disease pathology does not behave like a 'prion'

Alpha-synuclein protein involved in Parkinson's disease pathology does not behave like a 'prion'

In Parkinson's disease, the protein "alpha-synuclein" aggregates within neurons of patients and appears to propagate across interconnected areas of the brain. How this happens remains largely unknown. [More]
SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC). [More]
Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Gene therapy shows promise in children with Wiskott-Aldrich syndrome

Researchers reported promising preliminary outcomes for the first four children enrolled in a U.S. gene therapy trial for Wiskott-Aldrich syndrome (WAS), a life-threatening genetic blood and immune disorder, at the 57th annual meeting of the American Society of Hematology (abstract #260). [More]
Improved gene therapy treatment shows promise in mice with cystic fibrosis

Improved gene therapy treatment shows promise in mice with cystic fibrosis

An improved gene therapy treatment can cure mice with cystic fibrosis (CF). Cell cultures from CF patients, too, respond well to the treatment. Those are the encouraging results of a study presented by the Laboratory for Molecular Virology and Gene Therapy at KU Leuven, Belgium. [More]
Nightstar announces $35 million Series B financing round

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms. [More]
Scalable production of gene therapy vectors: an interview with Frank Ubags

Scalable production of gene therapy vectors: an interview with Frank Ubags

Gene therapy involves introducing genetic material into cells to replace missing or malfunctioning genes or to add a gene to express a beneficial protein in order to treat certain diseases, such as cancer or inherited disorders. [More]
enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

enGene, Janssen Biotech sign agreement to develop and commercialize new IBD therapies

enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary "Gene Pill" and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize new therapies for inflammatory bowel disease (IBD). [More]
Penn researchers show that canine X-linked retinitis pigmentosa can be cured over the long term

Penn researchers show that canine X-linked retinitis pigmentosa can be cured over the long term

Three years ago, a team from the University of Pennsylvania announced that they had cured X-linked retinitis pigmentosa, a blinding retinal disease, in dogs. Now they've shown that they can cure the canine disease over the long term, even when the treatment is given after half or more of the affected photoreceptor cells have been destroyed. [More]
Gene therapy for cystic fibrosis shows significant benefit in lung function

Gene therapy for cystic fibrosis shows significant benefit in lung function

For the first time gene therapy for cystic fibrosis has shown a significant benefit in lung function compared with placebo, in a phase 2 randomised trial published in The Lancet Respiratory Medicine journal. The technique replaces the defective gene response for cystic fibrosis by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells. [More]
Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age. [More]
Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia. [More]
Innovative gene transfer-based treatment for kids with giant axonal neuropathy

Innovative gene transfer-based treatment for kids with giant axonal neuropathy

University of North Carolina School of Medicine researchers have developed an innovative, experimental gene transfer-based treatment for children with giant axonal neuropathy (GAN). [More]

BRIM, Janssen announce strategic collaboration to develop effective treatment for dengue

BRIM Biotechnology, Inc., announced today that it has entered a Collaboration, Option and License Agreement with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. [More]
Brain protein key to binge drinking? An interview with Dr. Candice Contet

Brain protein key to binge drinking? An interview with Dr. Candice Contet

Alcohol binge drinking is mostly driven by positive reinforcement, a process in which a rewarding experience (e.g., the euphoria one feels when intoxicated) strengthens the behaviour leading to this experience (e.g., going to a bar). [More]
Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

Study finds similarity in clinical progression between human patients and Huntington's disease monkeys

Transgenic Huntington's disease monkeys show similarity to humans with Huntington's in their progressive neurodegeneration and decline of motor control, scientists from Yerkes National Primate Research Center, Emory University, report. [More]
Small-molecule drug simultaneously rejuvenates old muscles, aging brains

Small-molecule drug simultaneously rejuvenates old muscles, aging brains

Whether you're brainy, brawny or both, you may someday benefit from a drug found to rejuvenate aging brain and muscle tissue. Researchers at the University of California, Berkeley, have discovered that a small-molecule drug simultaneously perks up old stem cells in the brains and muscles of mice, a finding that could lead to drug interventions for humans that would make aging tissues throughout the body act young again. [More]
Advertisement
Advertisement